MRK — Merck & Co., Inc.

NYSE · Health Care · Pharmaceuticals · CIK 310158 ·
Last close
$119.60
Market Cap
$295.39B
52W High
$123.11
52W Low
$107.13
ADV30
11,026,363
Next earnings
2026-08-04
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 16,286,000,000 12,091,000,000 -3,201,000,000 -4,240,000,000 128,685,000,000 5,327,000,000 82,754,000,000
Dec 2025 16,400,000,000 10,849,000,000 4,065,000,000 2,963,000,000 136,866,000,000 14,565,000,000 84,204,000,000
Sep 2025 17,276,000,000 13,421,000,000 6,554,000,000 5,785,000,000 129,546,000,000 18,169,000,000 77,639,000,000
Jun 2025 15,806,000,000 12,249,000,000 5,552,000,000 4,427,000,000 117,523,000,000 8,007,000,000 68,463,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$17,890,000,000
Investing CF
$-22,464,000,000
Financing CF
$852,000,000
CapEx
$-3,775,000,000
Dividends Paid
$-8,231,000,000
Buybacks
$-4,794,000,000
EPS Diluted TTM
$3.55
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$66,721,000,000
Inventory
$6,479,000,000
Receivables
$12,210,000,000
ST Investments
$375,000,000
EBIT TTM
$13,152,000,000
Pretax Income TTM
$11,630,000,000
Interest Exp TTM
$1,522,000,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$65,768,001,536
EBITDA
$29,517,000,704
Free Cash Flow
$14,049,250,304
Enterprise Value
$338,858,999,808
Total Cash
$5,702,000,128
Total Debt
$49,116,999,680
Shares Out
2,469,824,415
Trailing EPS
$3.55
Book Value
$18.58
ROE
18.9%
ROA
12.6%
Div Yield
2.84%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 65,011,000,000 22,107,000,000 18,254,000,000 136,866,000,000 84,204,000,000 16,472,000,000
Dec 2024 64,168,000,000 20,221,000,000 17,117,000,000 117,106,000,000 70,734,000,000 21,468,000,000
Dec 2023 60,115,000,000 2,954,000,000 365,000,000 106,675,000,000 69,040,000,000 13,006,000,000
Dec 2022 59,283,000,000 18,282,000,000 14,519,000,000 109,160,000,000 63,102,000,000 19,095,000,000

TTM Snapshot

Revenues TTM
$53,137,000,000
NetIncome TTM
$12,566,000,000
OpCashFlow TTM
$0
Assets (Latest)
$117,106,000,000
Forward EPS
$9.56

Max Pain — expiry 2026-06-26

max pain strike: $115.00 · spot: $121.43 · call oi: 10,759 · put oi: 4,052
Expected Move to 2026-06-26: ±$2.42 (2.00%) — implied range $119.01$123.86 · ATM straddle on $121.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVS NOVARTIS AG $292.66B $153.38
NVSEF NOVARTIS AG $298.90B $156.65
AZN ASTRAZENECA PLC $280.74B $181.02
ABBV AbbVie Inc. $414.77B $234.76
NVO NOVO NORDISK A S $158.95B $47.42

News headlines (Yahoo Finance, 1h cache)

Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region
2026-06-24 19:05 · Yahoo
[Latest] Global Density Gradient Media Market Size/Share Worth USD 5.3 Billion by 2035 at a 11.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growt
2026-06-24 16:30 · Yahoo
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
2026-06-24 15:25 · Yahoo
Is Merck & Co., Inc. (MRK) Strengthening Its Vaccine Portfolio With New Capvaxive Approval?
2026-06-24 13:26 · Yahoo
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
2026-06-24 12:15 · Yahoo
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectab
2026-06-24 10:45 · Yahoo
How New Immunology and Vaccine Milestones At Merck (MRK) Have Changed Its Investment Story
2026-06-23 21:16 · Yahoo
The $50B Plan Merck Stock Was Broadcasting
2026-06-23 19:57 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-23 19:46 · Yahoo
Redditors Think Tempus AI (TEM) Still Has 10X Potential
2026-06-23 19:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.